Anavex Life Sciences Corp. – Consensus Indicates Potential 140.7% Upside – DirectorsTalk Interviews

Related Articles:

• Neuroprotective Mechanisms of Anavex 2-73 Revealed in Preclinical Study March 7, 2019 New preclinical data have shown for the first time the underlying mechanisms mediating the therapeutic activity of Anavex 2-73, an investigational therapy being evaluated for the treatment of neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). Anavex Life Sciences’ investigational activator of the sigma-1 receptor was found to exert its neuroprotective effect by re-establishing the normal functioning of cells’ “recycling…
• Phase 2 Study of Potential Oral Therapy for Parkinson’s Dementia, Anavex 2-73, Planned April 20, 2018 Anavex Life Sciences is planning to open a Phase 2 clinical trial testing Anavex 2-73, a potential oral treatment for patients with Parkinson’s disease dementia (PDD), this year. Anavex 2-73 aims to treat PDD by binding to the sigma-1 receptor, located in a cellular structure called the endoplasmic reticulum and important to protein production and transport. The proposed double-blind, placebo-controlled trial will…
• Phase 2 Trial Testing Anavex 2-73 Recruiting Parkinson’s Patients With Dementia in Spain November 1, 2018 The first patient has been enrolled in Anavex Life Sciences‘ Phase 2 clinical trial to evaluate the potential and safety of Anavex 2-73 as a treatment for Parkinson’s disease dementia. Now actively recruiting, the study (2017-004335-36) is expected to enroll approximately 120 Parkinson’s patients ages 50 or older with a dementia diagnosis. It is being conducted across several clinical sites in Spain,…
• Anavex 2-73 Therapy Candidate Seen to Restore Brain Cell Function in Mice with Parkinson’s, Study Finds October 31, 2017 Anavex 2-73, an investigational therapy being evaluated in clinical trials for Alzheimer’s disease, was found to restore the function of damaged nerve cells in mouse models of Parkinson’s disease. Based on the favorable safety profile seen in the clinic, the findings support the hypothesis that Anavex 2-73 might be a promising approach for treating Parkinson’s disease patients. The preclinical findings were presented at…
• Anavex 2-73 Trial Recruitment Reaches Halfway Mark March 13, 2019 A Phase 2 trial evaluating the efficacy and safety of investigational Anavex 2-73 as a treatment for Parkinson’s disease dementia has recruited half of its targeted patients, the therapy’s developer, Anavex Life Sciences, has announced. The study is still recruiting Parkinson’s disease patients age 50 or older who have been diagnosed with dementia. The Phase 2 trial is being conducted across several clinical sites in Spain,…
• Parkinson’s Dementia Trial of Oral Anavex 2-73 to Continue with Adjustments April 3, 2020 Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance related to the COVID-19 pandemic. A Phase 2 study of people with dementia linked to Parkinson’s disease is fully enrolled, and the company expects to announce topline results by June. Contingency plans are…
• Anavex Life Sciences Corp. - Consensus Indicates Potential 136.8% Upside - DirectorsTalk Interviews January 4, 2021 Anavex Life Sciences Corp. - Consensus Indicates Potential 136.8% Upside  DirectorsTalk Interviews
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer's Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting - GlobeNewswire March 28, 2019 Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer's Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting  GlobeNewswireNEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer's Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting - GlobeNewswire March 28, 2019 Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer's Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting  GlobeNewswireNEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome - GlobeNewswire June 25, 2019 Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome  GlobeNewswireNEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer's Association International Conference (AAIC) - GlobeNewswire July 17, 2019 Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer's Association International Conference (AAIC)  GlobeNewswireNEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer's Association International Conference (AAIC) - GlobeNewswire July 17, 2019 Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer's Association International Conference (AAIC)  GlobeNewswireNEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome - GlobeNewswire July 29, 2019 Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome  GlobeNewswireNEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome - GlobeNewswire July 31, 2019 Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome  GlobeNewswireNEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome - GlobeNewswire September 4, 2019 Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome  GlobeNewswireNEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
• Will Biogen Inc (NASDAQ: BIIB) Buy Anavex Life Sciences Corp (NASDAQ: AVXL)? - Insider Financial March 26, 2019 Will Biogen Inc (NASDAQ: BIIB) Buy Anavex Life Sciences Corp (NASDAQ: AVXL)?  Insider FinancialSmart biotech traders have been bidding up Anavex Life Sciences Corp (NASDAQ: AVXL) since the first of the year and could see a huge windfall if Biogen turns ...
• Anavex Life Sciences Corp (NASDAQ:AVXL) Eyes Further Gains After Breakout - Insider Financial May 23, 2019 Anavex Life Sciences Corp (NASDAQ:AVXL) Eyes Further Gains After Breakout  Insider FinancialIn true fashion and as predicted, 2019 is turning out to be a big year for Anavex Life Sciences Corp (NASDAQ: AVXL). The stock has continued to generate ...
• Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome - Yahoo Finance June 25, 2019 Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome  Yahoo FinanceNEW YORK, June 25, 2019 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company ...
• Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome - Yahoo Finance September 4, 2019 Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome  Yahoo FinanceAnavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the ...
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference - GlobeNewswire April 5, 2019 Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference  GlobeNewswireNEW YORK, April 05, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...